FreeStyle Libre 2 Discharge Trial

Last updated: April 7, 2023
Sponsor: Palo Alto Medical Foundation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hormone Deficiencies

Diabetes (Pediatric)

Diabetes Mellitus, Type 2

Treatment

N/A

Clinical Study ID

NCT05822232
2022.050-2
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to learn about the benefits of using aa Continuous Glucose Monitoring (CGM) system in patients with diabetes following discharge from the hospital. The main question it aims to answer is:

• If the use of CGM with alarms is safe and effective for managing low and/or high blood sugars when compared with performing finger sticks several times per day

Participants will wear one or two FreeStyle Libre CGM sensors for 12-14 days three times over a 12-week (3 month) period. This means that they will have the one to two sensors inserted under their skin. They will be asked to come to the study site four times and complete two phone calls with research staff over the 12-week period.

Researchers will compare the LibreView CGM group to the Standard of Care group to see if the use of continuous glucose monitoring (CGM) reduces risk of low blood sugar in patients with type 2 diabetes (T2D) after hospital discharge when compared with the current standard method.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Males and females ≥18 years of age admitted to general medicine and surgeryservices.
    1. Known history of T2D treated with oral antidiabetic agents (sulfonylureas,meglitinides, alpha-glucosidase inhibitors, thiazolidinedione, DPP-4 inhibitors,SGLT2- inhibitors), GLP1-RAs (exenatide, liraglutide, dulaglutide, semaglutide) orinsulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine, fast acting insulin aspart, insulin lispro]), intermediateacting (NPH and premixed formulations) or long-acting basal (glargine, detemir,degludec) formulations.
    1. Discharged on insulin therapy consisting of basal therapy 1) with or without bolusinsulin and also 2) with or without other diabetes drugs.

Exclusion

Exclusion Criteria:

    1. Subjects admitted with a diagnosis of diabetic ketoacidosis or hyperosmolarhyperglycemic state.
    1. Subjects using CGM technology prior to admission
    1. Subjects with type 1 diabetes
    1. Subjects not willing to receive insulin injections or test POC 4 times daily
    1. Subjects discharged from the hospital on diabetes therapy that does not includebasal insulin.
    1. Subjects not willing to wear a CGM device
    1. Pregnant women
    1. Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis andportal hypertension) and end-stage kidney disease (eGFR< 30 ml/min), dialysis,critically ill or terminal illness.
    1. Subjects with history of cognitive impairment, dementia, or mental conditionrendering the subject unable to understand the nature and consequences of the study.
    1. Subjects expected to be readmitted to the hospital within 3 months post-discharge.

Study Design

Total Participants: 100
Study Start date:
August 17, 2022
Estimated Completion Date:
April 30, 2024

Study Description

The purpose of this study is to look at the benefits of using Continuous Glucose Monitoring (CGM) system for patients with diabetes following discharge from the hospital. CGM devices measure blood sugar every few minutes using a sensor inserted under the skin.

In this study, we will compare the CGM method to the current usual (standard-of-care) method, which involves taking blood samples by fingerstick before meals and at bedtime. The CGM system recognizes low and high blood sugars throughout the day and night. The CGM system used in this study also has an alarm feature that alerts the user if blood sugar levels are too high or too low. In this study we will test if the use of CGM with alarms is safe and effective for managing low and/or high blood sugars when compared with performing finger sticks several times per day, which some diabetes patients find painful and burdensome.

In this study, 50% of participants will use the CGM method and 50% will use the fingerstick method to measure and control their glucose. The researchers will compare the two groups to answer the question if the use of continuous glucose monitoring (CGM) reduces risk of low blood sugar in patients with type 2 diabetes (T2D) after hospital discharge when compared with the current standard method.

Connect with a study center

  • Palo Alto Medical Foundation Research Institute

    Palo Alto, California 94301
    United States

    Active - Recruiting

  • Division of Endocrinology, Department of Medicine, Emory University School of Medicine

    Atlanta, Georgia 30322
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.